Works by Mikhael, Joseph

Results: 82
    1
    2

    Geriatric Assessment in Older Adults with Multiple Myeloma.

    Published in:
    Journal of the American Geriatrics Society, 2019, v. 67, n. 5, p. 987, doi. 10.1111/jgs.15715
    By:
    • Wildes, Tanya M.;
    • Tuchman, Sascha A.;
    • Klepin, Heidi D.;
    • Mikhael, Joseph;
    • Trinkaus, Kathryn;
    • Stockerl‐Goldstein, Keith;
    • Vij, Ravi;
    • Colditz, Graham
    Publication type:
    Article
    3
    4

    Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.

    Published in:
    2023
    By:
    • Martin, Thomas;
    • Dimopoulos, Meletios-Athanasios;
    • Mikhael, Joseph;
    • Yong, Kwee;
    • Capra, Marcelo;
    • Facon, Thierry;
    • Hajek, Roman;
    • Špička, Ivan;
    • Baker, Ross;
    • Kim, Kihyun;
    • Martinez, Gracia;
    • Min, Chang-Ki;
    • Pour, Ludek;
    • Leleu, Xavier;
    • Oriol, Albert;
    • Koh, Youngil;
    • Suzuki, Kenshi;
    • Casca, France;
    • Macé, Sandrine;
    • Risse, Marie-Laure
    Publication type:
    Correction Notice
    5

    Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
    By:
    • Martin, Thomas;
    • Dimopoulos, Meletios-Athanasios;
    • Mikhael, Joseph;
    • Yong, Kwee;
    • Capra, Marcelo;
    • Facon, Thierry;
    • Hajek, Roman;
    • Špička, Ivan;
    • Baker, Ross;
    • Kim, Kihyun;
    • Martinez, Gracia;
    • Min, Chang-Ki;
    • Pour, Ludek;
    • Leleu, Xavier;
    • Oriol, Albert;
    • Koh, Youngil;
    • Suzuki, Kenshi;
    • Casca, France;
    • Macé, Sandrine;
    • Risse, Marie-Laure
    Publication type:
    Article
    6
    7
    8

    Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
    By:
    • Martin, Thomas;
    • Dimopoulos, Meletios-Athanasios;
    • Mikhael, Joseph;
    • Yong, Kwee;
    • Capra, Marcelo;
    • Facon, Thierry;
    • Hajek, Roman;
    • Špička, Ivan;
    • Baker, Ross;
    • Kim, Kihyun;
    • Martinez, Gracia;
    • Min, Chang-Ki;
    • Pour, Ludek;
    • Leleu, Xavier;
    • Oriol, Albert;
    • Koh, Youngil;
    • Suzuki, Kenshi;
    • Casca, France;
    • Macé, Sandrine;
    • Risse, Marie-Laure
    Publication type:
    Article
    9

    Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00794-x
    By:
    • Fonseca, Rodrigo;
    • Arribas, Mariano;
    • Wiedmeier-Nutor, Julia E.;
    • Kusne, Yael N.;
    • González Vélez, Miguel;
    • Kosiorek, Heidi E.;
    • Butterfield, Richard J.;
    • Kirsch, Ilan R.;
    • Mikhael, Joseph R.;
    • Stewart, A. Keith;
    • Reeder, Craig;
    • Larsen, Jeremy;
    • Bergsagel, P. Leif;
    • Fonseca, Rafael
    Publication type:
    Article
    10

    Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
    By:
    • Martin, Thomas;
    • Dimopoulos, Meletios-Athanasios;
    • Mikhael, Joseph;
    • Yong, Kwee;
    • Capra, Marcelo;
    • Facon, Thierry;
    • Hajek, Roman;
    • Špička, Ivan;
    • Baker, Ross;
    • Kim, Kihyun;
    • Martinez, Gracia;
    • Min, Chang-Ki;
    • Pour, Ludek;
    • Leleu, Xavier;
    • Oriol, Albert;
    • Koh, Youngil;
    • Suzuki, Kenshi;
    • Casca, France;
    • Macé, Sandrine;
    • Risse, Marie-Laure
    Publication type:
    Article
    11

    Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00794-x
    By:
    • Fonseca, Rodrigo;
    • Arribas, Mariano;
    • Wiedmeier-Nutor, Julia E.;
    • Kusne, Yael N.;
    • González Vélez, Miguel;
    • Kosiorek, Heidi E.;
    • Butterfield, Richard J.;
    • Kirsch, Ilan R.;
    • Mikhael, Joseph R.;
    • Stewart, A. Keith;
    • Reeder, Craig;
    • Larsen, Jeremy;
    • Bergsagel, P. Leif;
    • Fonseca, Rafael
    Publication type:
    Article
    12
    13
    14
    15

    Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.

    Published in:
    Blood Cancer Journal, 2021, v. 11, n. 2, p. 1, doi. 10.1038/s41408-021-00432-4
    By:
    • Terpos, Evangelos;
    • Mikhael, Joseph;
    • Hajek, Roman;
    • Chari, Ajai;
    • Zweegman, Sonja;
    • Lee, Hans C.;
    • Mateos, María-Victoria;
    • Larocca, Alessandra;
    • Ramasamy, Karthik;
    • Kaiser, Martin;
    • Cook, Gordon;
    • Weisel, Katja C.;
    • Costello, Caitlin L.;
    • Elliott, Jennifer;
    • Palumbo, Antonio;
    • Usmani, Saad Z.
    Publication type:
    Article
    16
    17
    18
    19
    20
    21

    Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.

    Published in:
    American Journal of Hematology, 2023, v. 98, n. 1, p. E15, doi. 10.1002/ajh.26602
    By:
    • Dimopoulos, Meletios A.;
    • Moreau, Philippe;
    • Augustson, Bradley;
    • Castro, Nelson;
    • Pika, Tomas;
    • Delimpasi, Sosana;
    • De la Rubia, Javier;
    • Maiolino, Angelo;
    • Reiman, Tony;
    • Martinez‐Lopez, Joaquin;
    • Martin, Thomas;
    • Mikhael, Joseph;
    • Yong, Kwee;
    • Risse, Marie‐Laure;
    • Asset, Gaelle;
    • Marion, Sylvia;
    • Hajek, Roman
    Publication type:
    Article
    22
    23

    Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.

    Published in:
    American Journal of Hematology, 2017, v. 92, n. 5, p. 448, doi. 10.1002/ajh.24671
    By:
    • Bennani, N. Nora;
    • LaPlant, Betsy R.;
    • Ansell, Stephen M.;
    • Habermann, Thomas. M.;
    • Inwards, David J.;
    • Micallef, Ivana N.;
    • Johnston, Patrick B.;
    • Porrata, Luis F.;
    • Colgan, Joseph P.;
    • Markovic, Svetomir N.;
    • Nowakowski, Grzegorz S.;
    • Macon, William R.;
    • Reeder, Craig B.;
    • Mikhael, Joseph R.;
    • Northfelt, Donald W.;
    • Ghobrial, Irene M.;
    • Witzig, Thomas E.
    Publication type:
    Article
    24

    A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.

    Published in:
    American Journal of Hematology, 2017, v. 92, n. 5, p. 467, doi. 10.1002/ajh.24693
    By:
    • Rosenthal, Allison;
    • Dueck, Amylou C.;
    • Ansell, Stephen;
    • Gano, Katherine;
    • Conley, Christopher;
    • Nowakowski, Grzegorz S.;
    • Camoriano, John;
    • Leis, Jose F.;
    • Mikhael, Joseph R.;
    • Keith Stewart, A.;
    • Inwards, David;
    • Dingli, David;
    • Kumar, Shaji;
    • Noel, Pierre;
    • Gertz, Morie;
    • Porrata, Luis;
    • Russell, Stephen;
    • Colgan, Joseph;
    • Fonseca, Rafael;
    • Habermann, Thomas M.
    Publication type:
    Article
    25
    26

    Trends and outcomes of modern staging of solitary plasmacytoma of bone.

    Published in:
    American Journal of Hematology, 2012, v. 87, n. 7, p. 647, doi. 10.1002/ajh.23201
    By:
    • Warsame, Rahma;
    • Gertz, Morie A.;
    • Lacy, Martha Q.;
    • Kyle, Robert A.;
    • Buadi, Francis;
    • Dingli, David;
    • Greipp, Philip R.;
    • Hayman, Suzanne R.;
    • Kumar, Shaji K.;
    • Lust, John A.;
    • Russell, Stephen J.;
    • Witzig, Thomas E.;
    • Mikhael, Joseph;
    • Leung, Nelson;
    • Zeldenrust, Steven R.;
    • Rajkumar, S. Vincent;
    • Dispenzieri, Angela
    Publication type:
    Article
    27

    Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial.

    Published in:
    American Journal of Hematology, 2011, v. 86, n. 8, p. 640, doi. 10.1002/ajh.22053
    By:
    • Kumar, Shaji K.;
    • Lacy, Martha Q.;
    • Hayman, Suzanne R.;
    • Stewart, Keith;
    • Buadi, Francis K.;
    • Allred, Jacob;
    • Laumann, Kristina;
    • Greipp, Philip R.;
    • Lust, John A.;
    • Gertz, Morie A.;
    • Zeldenrust, Steven R.;
    • Bergsagel, P. Leif;
    • Reeder, Craig B.;
    • Witzig, Thomas E.;
    • Fonseca, Rafael;
    • Russell, Stephen J.;
    • Mikhael, Joseph R.;
    • Dingli, David;
    • Rajkumar, S. Vincent;
    • Dispenzieri, Angela
    Publication type:
    Article
    28

    The definition of IgM multiple myeloma.

    Published in:
    American Journal of Hematology, 2011, v. 86, n. 8, p. 718, doi. 10.1002/ajh.22080
    By:
    • Schuster, Steven R.;
    • Rajkumar, S. Vincent;
    • Dispenzieri, Angela;
    • Morice, William;
    • Aspitia, Alvaro Moreno;
    • Ansell, Stephen;
    • Kyle, Robert;
    • Mikhael, Joseph
    Publication type:
    Article
    29
    30
    31
    32

    Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.

    Published in:
    Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01149-w
    By:
    • Richardson, Paul G.;
    • Perrot, Aurore;
    • Mikhael, Joseph;
    • Martin, Thomas;
    • Beksac, Meral;
    • Spicka, Ivan;
    • Capra, Marcelo;
    • D'Agostino, Mattia;
    • Sonneveld, Pieter;
    • Bisht, Kamlesh;
    • Fukao, Taro;
    • Zhang, Rick;
    • Tada, Keisuke;
    • Tekle, Christina;
    • Macé, Sandrine;
    • Klippel, Zandra;
    • van de Velde, Helgi;
    • Moreau, Philippe
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39

    P-191: Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S142, doi. 10.1016/S2152-2650(21)02318-1
    By:
    • Chari, Ajai;
    • Dimopoulos, Meletios-Athanasios;
    • Beksac, Meral;
    • Leleu, Xavier;
    • Weisel, Katja;
    • Richter, Joshua;
    • Dirnberger, Franziska;
    • Iskander, Karim;
    • Yusuf, Akeem;
    • Mikhael, Joseph
    Publication type:
    Article
    40
    41
    42
    43
    44

    A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.

    Published in:
    2018
    By:
    • Padrnos, Leslie;
    • Ernst, Brenda;
    • Dueck, Amylou C.;
    • Kosiorek, Heidi E.;
    • Ginos, Brenda F.;
    • Toro, Angela;
    • Johnston, Patrick B.;
    • Habermann, Thomas M.;
    • Leis, Jose F.;
    • Mikhael, Joseph R.;
    • Nowakowski, Grzegorz S.;
    • Colgan, Joseph;
    • Porrata, Luis;
    • Ansell, Stephen M.;
    • Witzig, Thomas E.;
    • Reeder, Craig
    Publication type:
    journal article
    45
    46

    Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e27, doi. 10.1016/j.clml.2017.03.046
    By:
    • Kumar, Shaji;
    • Kaufman, Jonathan L.;
    • Mikhael, Joseph;
    • Gasparetto, Cristina;
    • Vij, Ravi;
    • Pegourie, Brigitte;
    • Benboubker, Lofti;
    • Facon, Thierry;
    • Moreau, Philippe;
    • Amiot, Martine;
    • Alzate, Stefanie;
    • Dunbar, Martin;
    • Xu, Tu;
    • Agarwal, Suresh;
    • Leverson, Joel;
    • Ross, Jeremy;
    • Maciag, Paulo;
    • Verdugo, Maria;
    • Touzeau, Cyrille
    Publication type:
    Article
    47
    48
    49
    50